Heart, Vascular & Thoracic Institute (Miller Family) Outcomes
Hypertrophic Obstructive Cardiomyopathy
Hypertrophic Obstructive Cardiomyopathy
Hypertrophic Obstructive Cardiomyopathy: Patient Volume
2017 - 2021
Hypertrophic obstructive cardiomyopathy (HOCM) is the thickening of the lower chambers of the heart. The septal muscle, which divides the right and left chambers, is especially affected by HOCM. The condition can impede blood flow from the heart to the aorta. Cleveland Clinic physicians use a comprehensive approach to diagnose and treat patients with HOCM. This includes a physical exam, electrocardiograph, chest X-ray, echocardiogram, and magnetic resonance imaging.
| Patient Type | 2017 Volume | 2018 Volume | 2019 Volume | 2020 Volume | 2021 Volume |
|---|---|---|---|---|---|
| Total HOCM outpatient visits | 3281 | 3714 | 4118 | 3390 | 4194 |
| New patients with HOCM | 541 | 720 | 781 | 592 | 804 |
HOCM = hypertrophic obstructive cardiomyopathy
Hypertrophic Obstructive Cardiomyopathy: Surgical Volume
2017 - 2021, N = 1121
Cleveland Clinic continues to be one of the national leaders in volume and treatment outcomes for patients with hypertrophic obstructive cardiomyopathy (HOCM).
Source: STS Adult Cardiac Surgery Database
In 2021, Cleveland Clinic surgeons performed 163 procedures to treat patients with HOCM.
Hypertrophic Obstructive Cardiomyopathy: Surgical Procedure Distribution
2021, N = 163
Cleveland Clinic surgeons perform isolated and a variety of combination procedures to treat patients with hypertrophic obstructive cardiomyopathy (HOCM).
CABG = coronary artery bypass grafting
Source: STS Adult Cardiac Surgery Database
ᵃProcedural percentages are rounded.
Septal Myectomy: In-Hospital Mortality
2017 – 2021, N = 914
The in-hospital mortality rates among patients who have septal myectomies at Cleveland Clinic are lower than the expected rates. Calculated observed to expected ratios remain less than the value of 1 indicating that Cleveland Clinic mortality is better than expected in these procedures.
| Year | O:E (observed to expected mortality ratio) |
|---|---|
| 2017 | 0.9 |
| 2018 | 0.7 |
| 2019 | 0.2 |
| 2020 | 0.0 |
| 2021 | 0.0 |
Source: Data from the Vizient Clinical Data Base used with permission of Vizient, Inc. All rights reserved.
Also see Hypertrophic Cardiomyopathy Center department page for more information.
